Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Oct 14 (Reuters) — Parabilis Medicines Inc: Parabilis Medicines Initiates Dose-ranging Clinical Study Of Zolucatetide In Familial Adenomatous Polyposis Parabilis Medicines - To Disclose Additional Fap Data From Phase 1/2 Trial In Q1 2027 Source text:... Further company coverage: PBLS.O (Reuters.Briefs@thomsonreuters.co
Parabilis Medicines launched a dose-ranging cohort in its Phase 1/2 trial testing zolucatetide in adults with familial adenomatous polyposis. Early proof-of-concept results were already presented from two FAP patients with desmoid tumors, showing meaningful reductions in duodenal polyp burden. The new cohort targets do
Parabilis Medicines initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis.